Imbalanced IL-1B and IL-18 Expression in Sezary Syndrome

Carregando...
Imagem de Miniatura
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Citação
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.24, n.5, article ID 4674, 13p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Sezary syndrome (SS) is a rare and aggressive type of cutaneous T-cell lymphoma, with an abnormal inflammatory response in affected skin. The cytokines IL-1B and IL-18, as key signaling molecules in the immune system, are produced in an inactive form and cleave to the active form by inflammasomes. In this study, we assessed the skin, serum, peripheral mononuclear blood cell (PBMC) and lymph-node samples of SS patients and control groups (healthy donors (HDs) and idiopathic erythroderma (IE) nodes) to investigate the inflammatory markers IL-1B and IL-18 at the protein and transcript expression levels, as potential markers of inflammasome activation. Our findings showed increased IL-1B and decreased IL-18 protein expression in the epidermis of SS patients; however, in the dermis layer, we detected increased IL-18 protein expression. In the lymph nodes of SS patients at advanced stages of the disease (N2/N3), we also detected an enhancement of IL-18 and a downregulation of IL-1B at the protein level. Moreover, the transcriptomic analysis of the SS and IE nodes confirmed the decreased expression of IL1B and NLRP3, whereas the pathway analysis indicated a further downregulation of IL1B-associated genes. Overall, the present findings showed compartmentalized expressions of IL-1B and IL-18 and provided the first evidence of their imbalance in patients with Sezary syndrome.
Palavras-chave
Sezary syndrome, lymph nodes, inflammasome, IL-1B, IL-18, erythroderma skin
Referências
  1. ABRAMS JT, 1991, J INVEST DERMATOL, V96, P31, DOI 10.1111/1523-1747.ep12514693
  2. Agar NS, 2010, J CLIN ONCOL, V28, P4730, DOI 10.1200/JCO.2009.27.7665
  3. Akeda T, 2014, ARCH DERMATOL RES, V306, P125, DOI 10.1007/s00403-013-1382-1
  4. Akilov OE, 2012, EXP DERMATOL, V21, P287, DOI 10.1111/j.1600-0625.2012.01452.x
  5. Andrews S, 2010, FASTQC QUALITY CONTR
  6. AXELROD PI, 1992, JAMA-J AM MED ASSOC, V267, P1354, DOI 10.1001/jama.267.10.1354
  7. Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0
  8. Birchenough GMH, 2016, SCIENCE, V352, P1535, DOI 10.1126/science.aaf7419
  9. Bossaller L, 2012, J IMMUNOL, V189, P5508, DOI 10.4049/jimmunol.1202121
  10. Bouaziz JD, 2005, J INVEST DERMATOL, V125, P1273, DOI 10.1111/j.0022-202X.2005.23914.x
  11. Breuer K, 2013, NUCLEIC ACIDS RES, V41, pD1228, DOI 10.1093/nar/gks1147
  12. Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002
  13. Cariti C, 2022, J AM ACAD DERMATOL, V86, P943, DOI 10.1016/j.jaad.2021.03.079
  14. Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
  15. Feldmeyer L, 2007, CURR BIOL, V17, P1140, DOI 10.1016/j.cub.2007.05.074
  16. GAZDAR AF, 1980, BLOOD, V55, P409
  17. Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
  18. Hacham M, 2002, EUR CYTOKINE NETW, V13, P55
  19. Hasegawa T, 2016, BIOCHEM BIOPH RES CO, V477, P329, DOI 10.1016/j.bbrc.2016.06.106
  20. Hirooka Y, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.639103
  21. KALTOFT K, 1987, ARCH DERMATOL RES, V279, P293, DOI 10.1007/BF00431220
  22. Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
  23. Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
  24. Linder A, 2022, METHODS MOL BIOL, V2523, P303, DOI 10.1007/978-1-0716-2449-4_19
  25. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  26. Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
  27. Manfrere KCG, 2016, ONCOTARGET, V7, P74592, DOI 10.18632/oncotarget.12816
  28. Mazodier K, 2005, BLOOD, V106, P3483, DOI 10.1182/blood-2005-05-1980
  29. Miyashiro D, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020936
  30. Monteleone M, 2015, CYTOKINE, V74, P213, DOI 10.1016/j.cyto.2015.03.022
  31. Mundy-Bosse B, 2018, BLOOD ADV, V2, P1818, DOI 10.1182/bloodadvances.2018020388
  32. Najidh S, 2021, BLOOD, V138, P2539, DOI 10.1182/blood.2021012286
  33. Nguyen V, 2008, J AM ACAD DERMATOL, V59, P949, DOI 10.1016/j.jaad.2008.08.030
  34. Novick D, 2001, CYTOKINE, V14, P334, DOI 10.1006/cyto.2001.0914
  35. OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0
  36. Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749
  37. Olsen EA, 2016, J AM ACAD DERMATOL, V74, P27, DOI 10.1016/j.jaad.2015.09.033
  38. Omoto Y, 2006, J IMMUNOL, V177, P8315, DOI 10.4049/jimmunol.177.12.8315
  39. Rothe MJ, 2005, CLIN DERMATOL, V23, P206, DOI 10.1016/j.clindermatol.2004.06.018
  40. Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
  41. Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
  42. Shi JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01849
  43. Sors A, 2006, BLOOD, V107, P2354, DOI 10.1182/blood-2005-06-2536
  44. Torrealba MP, 2018, ONCOTARGET, V9, P3497, DOI 10.18632/oncotarget.23334
  45. Wilcox RA, 2014, AM J HEMATOL, V89, P838, DOI 10.1002/ajh.23756
  46. Wise JF, 2013, BLOOD, V121, P4729, DOI 10.1182/blood-2012-12-471094
  47. Xie Zhuorui, 2021, Curr Protoc, V1, pe90, DOI 10.1002/cpz1.90
  48. Yamanaka K, 2006, CLIN CANCER RES, V12, P376, DOI 10.1158/1078-0432.CCR-05-1777
  49. Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995
  50. Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046
  51. Zhong FL, 2016, CELL, V167, P187, DOI 10.1016/j.cell.2016.09.001